abstract |
Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (.alpha.-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided. |